Skip to content

A clinical trial to study the effectiveness and safety of NEEMINT capsules in management of gastrointestinal disorders including Irritable bowel syndrome

An open label single arm clinical trial to evaluate the safety and efficacy of NEEMINT capsules in management of gastrointestinal disorders including irritable bowel syndrome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032735
Enrollment
15
Registered
2021-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K581- Irritable bowel syndrome with constipation Health Condition 2: K580- Irritable bowel syndrome with diarrhea Health Condition 3: K582- Mixed irritable bowel syndrome

Interventions

Intervention1: Neemint capsules (Each enteric coated capsule contains Neem Oil 350 mg and Peppermint Oil 150 mg): Dose: 2 capsules to be taken on empty stomach each day. Frequency: Once daily Route of

Sponsors

NUTRA GRACE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in the age group of 18-65 yrs (Inclusive of both genders). 2. Subjects with 2 or more symptoms like indigestion ,abdominal pain or cramps, nausea ,vomiting, bloating, constipation, diarrhoea, changes in bowel habits, loss of appetite. 3. Subjects/legal representative, willing to give a voluntary written informed consent. 4. Subjects should not participate in any other clinical study during participation in the current study

Exclusion criteria

Exclusion criteria: 1. Subjects with any cardiovascular, renal, respiratory or any other chronic illness. 2. Pregnant or lactating females. 3. Allergy to test product. 4. Any subject, in the investigators opinion not considered suitable for enrollment. 5. Subject participating in a similar clinical study, currently or during the previous 90 days

Design outcomes

Primary

MeasureTime frame
Change in Gastrointestinal Symptom Rating Scale [GSRS- IBS]Timepoint: Baseline, 1 week, 2 Weeks and 4 Weeks

Secondary

MeasureTime frame
Change in Subject�s Global Assessment of SymptomsTimepoint: Day 1 to Day 28;IBS- Quality of life questionnaireTimepoint: Baseline, Day 7, Day 14 and Day 28;Monitoring of AE and SAETimepoint: Day 1 to Day 14

Countries

India

Contacts

Public ContactMr Sunil Gupta

Pharexcel Consulting

info@pharexcelconsulting.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026